Can Akebia Therapeutics Inc (NASDAQ:AKBA)’s Tomorrow Be Different? The Stock Had Decline in Shorts

April 17, 2018 - By Hazel Jackson

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Logo

Investors sentiment decreased to 1.63 in 2017 Q4. Its down 0.60, from 2.23 in 2017Q3. It dived, as 15 investors sold Akebia Therapeutics, Inc. shares while 28 reduced holdings. 26 funds opened positions while 44 raised stakes. 30.27 million shares or 5.16% more from 28.78 million shares in 2017Q3 were reported.
Bank & Trust Of Montreal Can stated it has 67,639 shares or 0% of all its holdings. Pnc Finance Gru accumulated 0% or 48 shares. Wellington Mgmt Group Ltd Liability Partnership owns 376,926 shares for 0% of their portfolio. Mutual Of America Mgmt Limited reported 0.03% in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Eagle Asset Inc has 0.22% invested in Akebia Therapeutics, Inc. (NASDAQ:AKBA) for 2.72 million shares. Legal & General Grp Public Ltd Llc stated it has 11,105 shares. 1,500 are owned by Plante Moran Fin Ltd Liability. Blackrock accumulated 0% or 3.91M shares. State Common Retirement Fund owns 52,670 shares. Jacobs Levy Equity Inc invested 0.01% in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Goldman Sachs Group owns 683,920 shares or 0% of their US portfolio. Alliancebernstein L P holds 0% in Akebia Therapeutics, Inc. (NASDAQ:AKBA) or 43,200 shares. Hancock Holding Communications accumulated 0.04% or 66,900 shares. Amundi Pioneer Asset accumulated 0% or 2,700 shares. State Of Wisconsin Invest Board holds 0% or 26,000 shares in its portfolio.

Since February 15, 2018, it had 0 insider buys, and 1 insider sale for $14,620 activity.

The stock of Akebia Therapeutics Inc (NASDAQ:AKBA) registered a decrease of 0.36% in short interest. AKBA’s total short interest was 4.11M shares in April as published by FINRA. Its down 0.36% from 4.12M shares, reported previously. With 837,300 shares average volume, it will take short sellers 5 days to cover their AKBA’s short positions. The short interest to Akebia Therapeutics Inc’s float is 25.66%.

The stock decreased 1.01% or $0.1 during the last trading session, reaching $9.85. About 129,739 shares traded. Akebia Therapeutics, Inc. (NASDAQ:AKBA) has risen 5.85% since April 17, 2017 and is uptrending. It has underperformed by 5.70% the S&P500.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor biology. The company has market cap of $552.71 million. The Company’s lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. It currently has negative earnings. The firm is also developing a HIF portfolio of product candidates that include AKB-6899 for the treatment of anemia; and AKB-5169, a preclinical compound for the treatment for inflammatory bowel disease.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Ratings Coverage

Among 4 analysts covering Akebia Therapeutics (NASDAQ:AKBA), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Akebia Therapeutics had 4 analyst reports since November 2, 2017 according to SRatingsIntel. RBC Capital Markets maintained the stock with “Hold” rating in Thursday, November 2 report. The stock of Akebia Therapeutics, Inc. (NASDAQ:AKBA) has “Buy” rating given on Monday, December 18 by Piper Jaffray. The firm has “Buy” rating given on Thursday, December 7 by BTIG Research. The stock of Akebia Therapeutics, Inc. (NASDAQ:AKBA) earned “Buy” rating by Mizuho on Wednesday, March 7.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.